Hims and Hers Health Inc vs Vertiv Holdings Co — how do they compare? Hims and Hers Health Inc trades at $29.46 (market cap $6.55B), while Vertiv Holdings Co trades at $245.7 (market cap $93.83B). The key difference: Vertiv Holdings Co is far larger — about 14.3× Hims and Hers Health Inc's market cap, and Vertiv Holdings Co pays a 0.1% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Vertiv Holdings Co for 39 Days on average.
| HIMS | VRT | |
|---|---|---|
Market Cap | $6.55B | $93.83B |
Volume | 14,842,814 | 5,855,911 |
Sector | Health | Industrials |
52-Week High | $62.76 | $376.23 |
52-Week Low | $14.52 | $149.83 |
Typical Hold Time | 21 Days | 39 Days |
Enterprise Value | $7.25B | $94.06B |
Dividend Yield | — | 0.1% |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
Vertiv Holdings (VRT) trades at $244.94, down 0.63% for the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company demonstrates strong fundamental performance with Q2 2026 EPS of $1.52 beating estimates of $1.42, continuing a pattern of earnings surprises. Revenue growth remains robust at $11.5B projected for 2026, while profitability metrics show improvement with net income margin expanding to 15.09%. Recent news highlights VRT's strategic positioning in AI data center infrastructure, though legal investigations following a stock drop present near-term concerns.
The investment outlook remains positive based on strong analyst consensus with 95% buy ratings and a $364.94 price target representing 49% upside potential. Key opportunities include VRT's leadership in data center cooling solutions amid AI infrastructure growth, while risks involve potential securities law violations investigation and competitive pressures in the industrial technology sector. The company's cash flow generation remains healthy with $1.2B net cash flow projected for 2026, supporting continued business expansion.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →